Olema Pharmaceuticals inc
(NAS:OLMA)
$
6.15
-0.17 (-2.69%)
Market Cap: 466.46 Mil
Enterprise Value: 253.39 Mil
PE Ratio: 0
PB Ratio: 1.82
GF Score: 38/100 Olema Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023 / 06:00PM GMT
Release Date Price:
$10.6
(+12.05%)
Bill Maughan
Canaccord Genuity Wealth Management - Analyst
All right. Good afternoon. Thank you for joining us at the 43rd Annual Canaccord Genuity Growth Conference. I'm Bill Maughan, one of the biotech analysts here, and it's my pleasure to host Sean Bohen, CEO of Olema Oncology. Sean, thanks for joining us.
Sean Bohen
Olema Pharmaceuticals, Inc. - President & CEO
Thank you for having us, Bill.
Bill Maughan
Canaccord Genuity Wealth Management - Analyst
Of course. So just an easy one to start, can you give us a brief introduction to the company just for anybody who might not be intimately familiar with it?
Sean Bohen
Olema Pharmaceuticals, Inc. - President & CEO
Sure. Olema is a women's cancer-focused company. We're based in San Francisco. When I say San Francisco, I actually mean the city of San Francisco and Cambridge here in the Boston area. We went public in 2020 with a single clinical asset, which is our most advanced asset, which is a complete estrogen
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot